{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:51:51Z","timestamp":1777564311617,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Translational Research Grant of National Clinical Research Center for Hematologic Diseases","award":["No.2020ZKMB01"],"award-info":[{"award-number":["No.2020ZKMB01"]}]},{"name":"Translational Research Grant of National Clinical Research Center for Hematologic Diseases","award":["No.2021WWB02"],"award-info":[{"award-number":["No.2021WWB02"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.82000195"],"award-info":[{"award-number":["No.82000195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.81473486"],"award-info":[{"award-number":["No.81473486"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No. 82070203"],"award-info":[{"award-number":["No. 82070203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.81770210"],"award-info":[{"award-number":["No.81770210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.81270598"],"award-info":[{"award-number":["No.81270598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"crossref","award":["No.2018CXGC1213"],"award-info":[{"award-number":["No.2018CXGC1213"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Technology Development Projects of Shandong Province","award":["No.2017GSF18189"],"award-info":[{"award-number":["No.2017GSF18189"]}]},{"name":"Taishan Scholars Program of Shandong Province"},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["No.ZR201911140028"],"award-info":[{"award-number":["No.ZR201911140028"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Provincial Engineering Research Center of Lymphoma"},{"name":"Academic promotion programme of Shandong First Medical University"},{"name":"Shandong Provincial Hospital Youth Talent Plan"},{"name":"Shandong Provincial Hospital Research Incubation Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy\u00a0regimens and new therapeutic agents in decades. Some individuals could have promising response to standard therapy while others are unresponsive to standard chemotherapy or relapse after autologous hematopoietic\u00a0stem-cell transplantation\u00a0(ASCT), which indicates the necessity to develop novel therapies for refractory or relapsed B-NHLs. In recent years, a novel cell therapy, chimeric antigen receptor T-cell therapy (CAR-T), was invented to overcome the limitation of traditional treatments. Patients with aggressive B-NHL are considered for CAR-T cell therapy when they have progressive lymphoma after second-line chemotherapy, relapse after ASCT, or require a third-line therapy. Clinical trials of anti-CD19 CAR-T cell therapy have manifested encouraging efficacy in refractory or relapsed B-NHL. However, adverse effects of this cellular therapy including cytokine release syndrome, neurotoxicity, tumor lysis syndrome and\u00a0on-target, off-tumor toxicities should attract our enough attention despite the great anti-tumor effects of CAR-T cell therapy. Although CAR-T cell therapy has shown remarkable results in patients with B-NHL, the outcomes of patients with B-NHL were inferior to patients with acute lymphoblastic leukemia. The inferior response rate may be associated with physical barrier of lymphoma, tumor microenvironment and low quality of CAR-T cells manufactured from B-NHL patients. Besides, some patients relapsed after anti-CD19 CAR-T cell therapy, which possibly were\u00a0due to limited CAR-T cells persistence, CD19 antigen escape or antigen down-regulation. Quite a few new antigen-targeted CAR-T products and new-generation CAR-T, for example, CD20-targeted CAR-T, CD79b-targeted CAR-T, CD37-targeted CAR-T, multi-antigen-targeted CAR-T, armored CAR-T and four-generation CAR-T are developing rapidly\u00a0to figure out these deficiencies.<\/jats:p>","DOI":"10.1186\/s40364-021-00309-5","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T12:06:04Z","timestamp":1626177964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Zixun","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"309_CR1","doi-asserted-by":"publisher","unstructured":"Yang H, Green MR. Epigenetic programing of B-cell lymphoma by BCL6 and its genetic deregulation. Front Cell Dev Biol. 2019;7. https:\/\/doi.org\/10.3389\/fcell.2019.00272.","DOI":"10.3389\/fcell.2019.00272"},{"issue":"1","key":"309_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12\u201323. https:\/\/doi.org\/10.1038\/nrclinonc.2013.197.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"309_CR3","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(20)30031-4","volume":"7","author":"M Linschoten","year":"2020","unstructured":"Linschoten M, Kamphuis J, van Rhenen A, Bosman L, Cramer M, Doevendans P, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295\u2013308. https:\/\/doi.org\/10.1016\/S2352-3026(20)30031-4.","journal-title":"Lancet Haematol"},{"issue":"4","key":"309_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/hon.2613","volume":"37","author":"P Mondello","year":"2019","unstructured":"Mondello P, Mian M. Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP. Hematol Oncol. 2019;37(4):333\u201344. https:\/\/doi.org\/10.1002\/hon.2613.","journal-title":"Hematol Oncol"},{"issue":"1","key":"309_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31\u201346. https:\/\/doi.org\/10.1038\/nrclinonc.2017.128.","journal-title":"Nat Rev Clin Oncol"},{"key":"309_CR6","doi-asserted-by":"crossref","unstructured":"van Dorsten R, Lambson B, Wibmer C, Weinberg M, Moore P, Morris L. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. J Virol. 2020;94(2):e01533\u201319.","DOI":"10.1128\/JVI.01533-19"},{"issue":"11","key":"309_CR7","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1080\/10428194.2020.1786563","volume":"61","author":"P Johnson","year":"2020","unstructured":"Johnson P, Abramson J. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leuk Lymphoma. 2020;61(11):2561\u20137. https:\/\/doi.org\/10.1080\/10428194.2020.1786563.","journal-title":"Leuk Lymphoma"},{"key":"309_CR8","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.blre.2019.100640","volume":"40","author":"V Bachanova","year":"2020","unstructured":"Bachanova V, Perales M, Abramson J. Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy. Blood Rev. 2020;40:100640. https:\/\/doi.org\/10.1016\/j.blre.2019.100640.","journal-title":"Blood Rev"},{"issue":"26","key":"309_CR9","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1708566.","journal-title":"N Engl J Med"},{"issue":"4","key":"309_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.25315","volume":"84","author":"JS Gofshteyn","year":"2018","unstructured":"Gofshteyn JS, Shaw PA, Teachey DT, Grupp SA, Maude S, Banwell B, et al. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol. 2018;84(4):537\u201346. https:\/\/doi.org\/10.1002\/ana.25315.","journal-title":"Ann Neurol"},{"issue":"9967","key":"309_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet"},{"issue":"16","key":"309_CR12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"1","key":"309_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.retram.2019.12.001","volume":"68","author":"I Danylesko","year":"2020","unstructured":"Danylesko I, Chowers G, Shouval R, Besser M, Jacoby E, Shimoni A, et al. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Curr Res Transl Med. 2020;68(1):17\u201322. https:\/\/doi.org\/10.1016\/j.retram.2019.12.001.","journal-title":"Curr Res Transl Med"},{"key":"309_CR14","doi-asserted-by":"crossref","unstructured":"Klener P. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. Int J Mol Sci. 2019;20(18):4417.","DOI":"10.3390\/ijms20184417"},{"issue":"4","key":"309_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11899-019-00520-0","volume":"14","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Barta SK. Mantle cell lymphoma: which patients should we transplant? Curr Hematol Malig Rep. 2019;14(4):239\u201346. https:\/\/doi.org\/10.1007\/s11899-019-00520-0.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"309_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.beha.2017.10.010","volume":"31","author":"PC Arora","year":"2018","unstructured":"Arora PC, Portell CA. Novel therapies for relapsed\/refractory mantle cell lymphoma. Best Pract Res Clin Haematol. 2018;31(1):105\u201313. https:\/\/doi.org\/10.1016\/j.beha.2017.10.010.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"14","key":"309_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"issue":"26","key":"309_CR18","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1200\/JCO.2005.05.012","volume":"23","author":"IS Lossos","year":"2005","unstructured":"Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23(26):6351\u20137. https:\/\/doi.org\/10.1200\/JCO.2005.05.012.","journal-title":"J Clin Oncol"},{"issue":"1","key":"309_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.020.","journal-title":"Mol Ther"},{"issue":"26","key":"309_CR20","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"S Neelapu","year":"2017","unstructured":"Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"1","key":"309_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"issue":"16","key":"309_CR22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u201313. https:\/\/doi.org\/10.1200\/JCO.2016.71.3024.","journal-title":"J Clin Oncol"},{"issue":"11","key":"309_CR23","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.013.","journal-title":"Mol Ther"},{"issue":"2","key":"309_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno JN, Lam N, Vanasse D, Shen Y-W, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270\u201380. https:\/\/doi.org\/10.1038\/s41591-019-0737-3.","journal-title":"Nat Med"},{"issue":"1","key":"309_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"10254","key":"309_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"J Abramson","year":"2020","unstructured":"Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London, England). 2020;396(10254):839\u201352.","journal-title":"Lancet (London, England)"},{"issue":"13","key":"309_CR27","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"C Pinnix","year":"2020","unstructured":"Pinnix C, Gunther J, Dabaja B, Strati P, Fang P, Hawkins M, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4(13):2871\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2020001837.","journal-title":"Blood Adv"},{"issue":"19","key":"309_CR28","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u2013911. https:\/\/doi.org\/10.1182\/bloodadvances.2020002394.","journal-title":"Blood Adv"},{"issue":"4","key":"309_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","volume":"22","author":"J-X Cao","year":"2020","unstructured":"Cao J-X, Wang H, Gao W-J, You J, Wu L-H, Wang Z-X. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor\u2013T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020;22(4):214\u201326. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.015.","journal-title":"Cytotherapy"},{"issue":"1","key":"309_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Rev Clin Oncol. 2017;15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"309_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","volume":"11","author":"D Liu","year":"2018","unstructured":"Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11(1):121. https:\/\/doi.org\/10.1186\/s13045-018-0653-x.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"309_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4. https:\/\/doi.org\/10.1186\/s40364-018-0116-0.","journal-title":"Biomark Res"},{"key":"309_CR33","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3389\/fonc.2020.00885","volume":"10","author":"S Sievers","year":"2020","unstructured":"Sievers S, Watson G, Johncy S, Adkins S. Recognizing and grading CAR T-cell toxicities: an advanced practitioner perspective. Front Oncol. 2020;10:885. https:\/\/doi.org\/10.3389\/fonc.2020.00885.","journal-title":"Front Oncol"},{"issue":"5","key":"309_CR34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","volume":"13","author":"H Chen","year":"2019","unstructured":"Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 2019;13(5):610\u20137. https:\/\/doi.org\/10.1007\/s11684-019-0714-8.","journal-title":"Front Med"},{"issue":"8","key":"309_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813\u201322. https:\/\/doi.org\/10.1080\/1744666X.2019.1629904.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"309_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028.","journal-title":"Oncologist"},{"key":"309_CR37","doi-asserted-by":"crossref","unstructured":"Huarte E, O'Conner RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, et al. Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy. Clin Cancer Res. 2020;26(23):6299\u2013309.","DOI":"10.1158\/1078-0432.CCR-20-1739"},{"issue":"6","key":"309_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"issue":"1","key":"309_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9(1):15. https:\/\/doi.org\/10.1186\/s40164-020-00171-5.","journal-title":"Exp Hematol Oncol"},{"issue":"20","key":"309_CR40","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan J, Forst D, Arrillaga-Romany I, Batchelor T, Baehring J, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u201321. https:\/\/doi.org\/10.1182\/blood-2018-12-893396.","journal-title":"Blood"},{"issue":"1","key":"309_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","volume":"8","author":"M Du","year":"2020","unstructured":"Du M, Hari P, Hu Y, Mei H. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomark Res. 2020;8(1):13. https:\/\/doi.org\/10.1186\/s40364-020-00190-8.","journal-title":"Biomark Res"},{"issue":"5","key":"309_CR42","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"D Rubin","year":"2019","unstructured":"Rubin D, Danish H, Ali A, Li K, LaRose S, Monk A, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain J Neurol. 2019;142(5):1334\u201348. https:\/\/doi.org\/10.1093\/brain\/awz053.","journal-title":"Brain J Neurol"},{"issue":"S1","key":"309_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"S Neelapu","year":"2019","unstructured":"Neelapu S. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(S1):48\u201352. https:\/\/doi.org\/10.1002\/hon.2595.","journal-title":"Hematol Oncol"},{"issue":"9","key":"309_CR44","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00134-020-06193-1","volume":"46","author":"E Azoulay","year":"2020","unstructured":"Azoulay E, Darmon M, Valade S. Acute life-threatening toxicity from CAR T-cell therapy. Intensive Care Med. 2020;46(9):1723\u20136. https:\/\/doi.org\/10.1007\/s00134-020-06193-1.","journal-title":"Intensive Care Med"},{"issue":"13","key":"309_CR45","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati P, Ahmed S, Kebriaei P, Nastoupil L, Claussen C, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2020002328.","journal-title":"Blood Adv"},{"issue":"7","key":"309_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"R Sterner","year":"2019","unstructured":"Sterner R, Sakemura R, Cox M, Yang N, Khadka R, Forsman C, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722.","journal-title":"Blood"},{"issue":"8","key":"309_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","volume":"21","author":"J Rice","year":"2019","unstructured":"Rice J, Nagle S, Randall J, Hinson H. Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment. Curr Treat Options Neurol. 2019;21(8):40. https:\/\/doi.org\/10.1007\/s11940-019-0580-3.","journal-title":"Curr Treat Options Neurol"},{"issue":"16","key":"309_CR48","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati P, Nastoupil L, Westin J, Fayad L, Ahmed S, Fowler N, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(16):3943\u201351. https:\/\/doi.org\/10.1182\/bloodadvances.2020002228.","journal-title":"Blood Adv"},{"issue":"12","key":"309_CR49","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","volume":"33","author":"M Mohty","year":"2019","unstructured":"Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33(12):2767\u201378. https:\/\/doi.org\/10.1038\/s41375-019-0615-5.","journal-title":"Leukemia"},{"issue":"8","key":"309_CR50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/hum.2015.054","volume":"26","author":"G Enblad","year":"2015","unstructured":"Enblad G, Karlsson H, Loskog A. CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. Hum Gene Ther. 2015;26(8):498\u2013505. https:\/\/doi.org\/10.1089\/hum.2015.054.","journal-title":"Hum Gene Ther"},{"key":"309_CR51","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell D, Guedan S. CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol. 2020;11:1109. https:\/\/doi.org\/10.3389\/fimmu.2020.01109.","journal-title":"Front Immunol"},{"issue":"3","key":"309_CR52","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1172\/JCI128672","volume":"130","author":"Z Freeman","year":"2020","unstructured":"Freeman Z, Nirschl T, Hovelson D, Johnston R, Engelhardt J, Selby M, et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J Clin Invest. 2020;130(3):1405\u201316. https:\/\/doi.org\/10.1172\/JCI128672.","journal-title":"J Clin Invest"},{"key":"309_CR53","doi-asserted-by":"publisher","first-page":"590941","DOI":"10.3389\/fonc.2020.590941","volume":"10","author":"Z Ge","year":"2020","unstructured":"Ge Z, Ding S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Front Oncol. 2020;10:590941. https:\/\/doi.org\/10.3389\/fonc.2020.590941.","journal-title":"Front Oncol"},{"issue":"4","key":"309_CR54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/pin.12259","volume":"65","author":"Y Komohara","year":"2015","unstructured":"Komohara Y, Niino D, Ohnishi K, Ohshima K, Takeya M. Role of tumor-associated macrophages in hematological malignancies. Pathol Int. 2015;65(4):170\u20136. https:\/\/doi.org\/10.1111\/pin.12259.","journal-title":"Pathol Int"},{"issue":"1","key":"309_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-020-00198-0","volume":"8","author":"L Qin","year":"2020","unstructured":"Qin L, Zhao R, Chen D, Wei X, Wu Q, Long Y, et al. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res. 2020;8(1):19. https:\/\/doi.org\/10.1186\/s40364-020-00198-0.","journal-title":"Biomark Res"},{"issue":"18","key":"309_CR56","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"V Boussiotis","year":"2016","unstructured":"Boussiotis V. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378. https:\/\/doi.org\/10.1056\/NEJMra1514296.","journal-title":"N Engl J Med"},{"key":"309_CR57","doi-asserted-by":"crossref","unstructured":"Itzhaki O, Jacoby E, Nissani A, Levi M, Nagler A, Kubi A, et al. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. J Immunother Cancer. 2020;8(1):e000148.","DOI":"10.1136\/jitc-2019-000148"},{"key":"309_CR58","doi-asserted-by":"crossref","unstructured":"Stock S, Schmitt M, Sellner L. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci. 2019;20(24):6223.","DOI":"10.3390\/ijms20246223"},{"key":"309_CR59","doi-asserted-by":"publisher","first-page":"583716","DOI":"10.3389\/fimmu.2020.583716","volume":"11","author":"C Perez","year":"2020","unstructured":"Perez C, Gruber I, Arber C. Off-the-shelf allogeneic T cell therapies for Cancer: opportunities and challenges using naturally occurring \"universal\" donor T cells. Front Immunol. 2020;11:583716. https:\/\/doi.org\/10.3389\/fimmu.2020.583716.","journal-title":"Front Immunol"},{"issue":"3","key":"309_CR60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp S, Mufti G, Poirot L. Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"309_CR61","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353. https:\/\/doi.org\/10.1038\/s41591-019-0421-7.","journal-title":"Nat Med"},{"key":"309_CR62","doi-asserted-by":"crossref","unstructured":"Qin H, Dong Z, Wang X, Cheng W, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019;11(511):eaaw9414.","DOI":"10.1126\/scitranslmed.aaw9414"},{"issue":"2","key":"309_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.critrevonc.2014.02.004","volume":"91","author":"S Yang","year":"2014","unstructured":"Yang S, Li J, Xu W. Role of BAFF\/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit Rev Oncol Hematol. 2014;91(2):113\u201322. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.02.004.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"309_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00259-018-4214-x","volume":"46","author":"K Zettlitz","year":"2019","unstructured":"Zettlitz K, Tavar\u00e9 R, Tsai W, Yamada R, Ha N, Collins J, et al. F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. Eur J Nucl Med Mol Imaging. 2019;46(2):489\u2013500. https:\/\/doi.org\/10.1007\/s00259-018-4214-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"309_CR65","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506. https:\/\/doi.org\/10.3324\/haematol.2019.243543.","journal-title":"Haematologica"},{"issue":"2","key":"309_CR66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","volume":"155","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang W, Han Q, Liu Y, Dai H, Guo Y, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol (Orlando, Fla). 2014;155(2):160\u201375.","journal-title":"Clin Immunol (Orlando, Fla)"},{"issue":"16","key":"309_CR67","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1002\/cam4.3259","volume":"9","author":"W Sang","year":"2020","unstructured":"Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020;9(16):5827\u201338. https:\/\/doi.org\/10.1002\/cam4.3259.","journal-title":"Cancer Med"},{"issue":"14","key":"309_CR68","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood.2020005278","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344. https:\/\/doi.org\/10.1182\/blood.2020005278.","journal-title":"Blood"},{"issue":"36","key":"309_CR69","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1021\/jacs.7b03208","volume":"139","author":"W Peng","year":"2017","unstructured":"Peng W, Paulson J. CD22 ligands on a natural N-glycan scaffold efficiently deliver toxins to B-lymphoma cells. J Am Chem Soc. 2017;139(36):12450\u20138. https:\/\/doi.org\/10.1021\/jacs.7b03208.","journal-title":"J Am Chem Soc"},{"issue":"17","key":"309_CR70","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1182\/blood.2020009432","volume":"137","author":"JH Baird","year":"2021","unstructured":"Baird JH, Frank MJ, Craig J, Patel S, Spiegel JY, Sahaf B, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2021;137(17):2321\u20135. https:\/\/doi.org\/10.1182\/blood.2020009432.","journal-title":"Blood"},{"issue":"1","key":"309_CR71","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-019-0741-6","volume":"12","author":"H Jia","year":"2019","unstructured":"Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C, et al. Haploidentical CD19\/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. J Hematol Oncol. 2019;12(1):57. https:\/\/doi.org\/10.1186\/s13045-019-0741-6.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"309_CR72","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jcyt.2020.01.008","volume":"22","author":"C Zeng","year":"2020","unstructured":"Zeng C, Cheng J, Li T, Huang J, Li C, Jiang L, et al. Efficacy and toxicity for CD22\/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020;22(3):166\u201371. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.008.","journal-title":"Cytotherapy"},{"key":"309_CR73","doi-asserted-by":"crossref","unstructured":"Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021;13(586):eabc6401.","DOI":"10.1126\/scitranslmed.abc6401"},{"issue":"3","key":"309_CR74","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","volume":"15","author":"S Ding","year":"2020","unstructured":"Ding S, Mao X, Cao Y, Wang N, Xu H, Zhou J. Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Target Oncol. 2020;15(3):365\u201375. https:\/\/doi.org\/10.1007\/s11523-020-00729-7.","journal-title":"Target Oncol"},{"issue":"14","key":"309_CR75","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarf\u00f2","year":"2018","unstructured":"Scarf\u00f2 I, Ormh\u00f8j M, Frigault M, Castano A, Lorrey S, Bouffard A, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018;132(14):1495\u2013506. https:\/\/doi.org\/10.1182\/blood-2018-04-842708.","journal-title":"Blood"},{"issue":"8","key":"309_CR76","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","volume":"3","author":"H K\u00f6ksal","year":"2019","unstructured":"K\u00f6ksal H, Dillard P, Josefsson S, Maggadottir S, Pollmann S, F\u00e5ne A, et al. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood Adv. 2019;3(8):1230\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2018029678.","journal-title":"Blood Adv"},{"issue":"26","key":"309_CR77","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","volume":"128","author":"Z Xu-Monette","year":"2016","unstructured":"Xu-Monette Z, Li L, Byrd J, Jabbar K, Manyam G, Maria de Winde C, et al. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016;128(26):3083\u2013100. https:\/\/doi.org\/10.1182\/blood-2016-05-715094.","journal-title":"Blood"},{"issue":"4","key":"309_CR78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel S, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203\u201320. https:\/\/doi.org\/10.1038\/nrclinonc.2016.168.","journal-title":"Nat Rev Clin Oncol"},{"key":"309_CR79","doi-asserted-by":"publisher","first-page":"108382","DOI":"10.1016\/j.clim.2020.108382","volume":"214","author":"W Song","year":"2020","unstructured":"Song W, Zhang M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol (Orlando, Fla). 2020;214:108382.","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"309_CR80","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, et al. Anti-CD19 chimeric antigen receptor T cells in combination with Nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma. Front Oncol. 2019;9:767. https:\/\/doi.org\/10.3389\/fonc.2019.00767.","journal-title":"Front Oncol"},{"key":"309_CR81","doi-asserted-by":"crossref","unstructured":"Tao L, Farooq M, Gao Y, Zhang L, Niu C, Ajmal I, et al. CD19-CAR-T Cells Bearing a KIR\/PD-1-Based Inhibitory CAR Eradicate CD19HLA-C1 Malignant B Cells While Sparing CD19HLA-C1 Healthy B Cells. Cancers. 2020;12(9):2612.","DOI":"10.3390\/cancers12092612"},{"issue":"2","key":"309_CR82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1042\/BST20170178","volume":"46","author":"L Ebert","year":"2018","unstructured":"Ebert L, Yu W, Gargett T, Brown M. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochem Soc Trans. 2018;46(2):391\u2013401. https:\/\/doi.org\/10.1042\/BST20170178.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"309_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12(1):128. https:\/\/doi.org\/10.1186\/s13045-019-0813-7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"309_CR84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","volume":"12","author":"S Ayyappan","year":"2019","unstructured":"Ayyappan S, Maddocks K. Novel and emerging therapies for B cell lymphoma. J Hematol Oncol. 2019;12(1):82. https:\/\/doi.org\/10.1186\/s13045-019-0752-3.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"309_CR85","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"O Yeku","year":"2016","unstructured":"Yeku O, Brentjens R. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44(2):412\u20138. https:\/\/doi.org\/10.1042\/BST20150291.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"309_CR86","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86. https:\/\/doi.org\/10.1186\/s13045-020-00910-5.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"309_CR87","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145\u201354. https:\/\/doi.org\/10.1517\/14712598.2015.1046430.","journal-title":"Expert Opin Biol Ther"},{"key":"309_CR88","doi-asserted-by":"crossref","unstructured":"Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T Cells: More than Ease of Access? Cells. 2018;7(10):155.","DOI":"10.3390\/cells7100155"},{"issue":"6","key":"309_CR89","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/MOH.0000000000000181","volume":"22","author":"Y Yang","year":"2015","unstructured":"Yang Y, Jacoby E, Fry T. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015;22(6):509\u201315. https:\/\/doi.org\/10.1097\/MOH.0000000000000181.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"309_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 2019;12(1):69. https:\/\/doi.org\/10.1186\/s13045-019-0763-0.","journal-title":"J Hematol Oncol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-021-00309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-021-00309-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-021-00309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T12:19:36Z","timestamp":1626178776000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-021-00309-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1186\/s40364-021-00309-5","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}